arrow
Z

Zachary R. Hunter

Dana-Farber Cancer Institute
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemoimmunotherapy-associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20-directed cellular therapies

华氏巨球蛋白血症中与化疗免疫疗法相关的CD20 (<i>MS4A1</i>) 耐药突变:与表达无关的表位破坏,对CD20靶向细胞疗法的意义

2026-10-010
OAAI
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia

WNK2致癌性通过在MYD88突变的华氏巨球蛋白血症中发现并功能表征新型基因异构体得以揭示

2026-07-080
OA
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells

泽布替尼和匹鲁替尼在MYD88突变淋巴瘤细胞中表现出协同杀伤和抑制BTK信号通路

2026-04-170
OAAI
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

II期伊布替尼和维奈克拉联合治疗初治华氏巨球蛋白血症的最终研究报告

2026-03-150
PRE
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications

维奈克拉或匹鲁托鲁替尼在复发/难治性华氏巨球蛋白血症中的临床与分子预测因子及序贯治疗意义

2026-03-070
PRE
Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström macroglobulinemia

奥妥珠单抗初始给药及后续剂量减少对华氏巨球蛋白血症患者的影响

2026-01-010
OAAI
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia

利妥昔单抗单药治疗既往治疗过的华氏巨球蛋白血症患者长期随访研究

2025-07-210
OAAI
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

多发性骨髓瘤和Waldenström巨球蛋白血症患者对SARS-CoV-2加强疫苗免疫原性的前瞻性研究

2025-06-090
OAAI
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia

单细胞RNA测序定义了不同的疾病亚型,并揭示了无症状华氏巨球蛋白血症中干扰素低反应性。

2025-02-100
OA
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
2025-01-211
OAAI
Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenstrom Macroglobulinemia

二线随访:接受伊布替尼和维奈克拉治疗的症状性、初治华氏巨球蛋白血症患者

BLOOD
IF23.1
2024-11-050
PRE
Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2-Inhibitors

一种新型双功能Protac Jh-XIII-05-1的开发与表征:该化合物显示出对IRAK1和IRAK4激酶的强效抑制及靶点降解作用,并且在MYD88突变的B细胞淋巴瘤细胞中单独使用或与BTK-和BCL2-抑制剂联用均表现出高度活性。

BLOOD
IF23.1
2024-11-050
PRE
Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy

通过系列单细胞测序的基因组进化识别Waldenstrom's Macroglobulinemia患者在ibrutinib单药治疗过程中LYN高表达作为耐药性的促进因子

BLOOD
IF23.1
2024-11-050
PRE